Left bundle branch pacing in patients with structural heart disease: personalizing cardiac resynchronization therapy
- PMID: 40726437
- PMCID: PMC12530354
- DOI: 10.1093/europace/euaf154
Left bundle branch pacing in patients with structural heart disease: personalizing cardiac resynchronization therapy
Abstract
Biventricular pacing remains the cornerstone of cardiac resynchronization therapy (CRT) in patients with heart failure, with well-established benefits. Left bundle branch pacing (LBBP) offers a physiologic alternative by engaging the native conduction system to restore synchrony and has generated significant enthusiasm. However, the growing adoption of LBBP should be tempered by recognition that a one-size-fits-all approach may not address the underlying substrate, particularly in those with intraventricular conduction delay. While a less-than-optimal LBBP implant may be sufficient in bradycardia patients, its adequacy in heart failure patients, who may require more precise consideration of conduction disease, remains uncertain. This review gives a comprehensive framework for integrating LBBP into CRT, including pre-implant, intraprocedural, and post-implant assessment. It also provides practical guidance on when to pursue LBBP alone, when to supplement with a coronary sinus lead, and when to consider conventional biventricular pacing, with an emphasis on a personalized approach to the underlying conduction substrate for maximal therapeutic benefit.
Keywords: Biventricular pacing; Cardiac resynchronization therapy; Conduction system pacing; Heart failure; Intraventricular conduction delay; Left bundle branch block; Left bundle branch pacing.
© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.
Conflict of interest statement
Conflict of interest: J.J. reports investigator-initiated external research funds from Medtronic Inc. and consultancy for Abbott and Medtronic Inc. J.L. reports external research funds from Medtronic Inc. and consultancy for Medtronic Inc. M.J. declares consultancy, proctoring, speaker fees, and/or advisory board honoraria from Medtronic, Biotronik, Abbott, and Boston Scientific. H.B. has received speaker fees and institutional research grants from Abbott, Biotronik, Boston Scientific, Medtronic, and MicroPort. P.V. reports receiving consultation, honoraria, research, and fellowship grants from Medtronic and honoraria and consultant fees from Abbott, Biotronik, and Boston Scientific and has a patent for HBP delivery tool. K.V. received research and educational grants from Medtronic, Abbott, Biosense Webster, and Philips all paid to the institute and is a consultant for Medtronic, Abbott, Boston Scientific, and Biosense Webster. All other authors have no conflicts to declare.
Figures
References
-
- Glikson M, Burri H, Abdin A, Cano O, Curila K, De Pooter J et al. European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with special contribution of the European Heart Rhythm Association of the ESC and endorsed by the Asia Pacific Heart Rhythm Society, the Canadian Heart Rhythm Society, the Heart Rhythm Society, and the Latin American Heart Rhythm Society. Europace 2025;27:euaf050. - PMC - PubMed
-
- Vijayaraman P, Sharma PS, Cano O, Ponnusamy SS, Herweg B, Zanon F et al. Comparison of left bundle branch area pacing and biventricular pacing in candidates for resynchronization therapy. J Am Coll Cardiol 2023;82:228–41. - PubMed
-
- Vijayaraman P, Zanon F, Ponnusamy SS, Herweg B, Sharma P, Molina-Lerma M et al. Conduction system pacing compared with biventricular pacing for cardiac resynchronization therapy in patients with heart failure and mildly reduced left ventricular ejection fraction: Results from International Collaborative LBBAP Study (I-CLAS) Group. Heart Rhythm 2025;22:1512–22. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
